TG Therapeutics Announces Approximately $85 million in Equity and Debt Financings
NEW YORK, March 01, 2019 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, today announced approximately $85 million in equity and debt...
Read moreTG Therapeutics Announces Positive Data Safety Monitoring Board Reviews of UNITY-CLL and UNITY-NHL Clinical Trials
Vestibulum iaculis lacinia est. Proin dicm elementum velit. Fusce euismod consequat ante. Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Pellentesque sed dolor. Aliquam congue fermentum nisl…
Read more